Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · AKUMS DRUGS AND PHARMA L · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
AKUMS DRUGS AND PHARMA L
NSE: AKUMS · BSE: 544222
NSE: AKUMS · BSE: 544222
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
AKUMS DRUGS AND PHARMA L
StateQ1 FY27 filed
Last close · 27 Oct 2026₹715.20
Market cap₹11.0k cr
TTM P/E · P/B · EV/EBITDA37.5 · 3.29 · 15.6
AKUMS DRUGS AND PHARMA L is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY25–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 4,118 | 4,359 |
| EBITDA (ex other income) | 481 | 502 |
| margin % | 11.7 | 11.5 |
| Owners' profit | 338 | 255 |
| EPS, as reported (₹) | 22.60 | 16.67 |
| ROE % · ROCE % | 11.2 · 11.8 | 7.7 · 10.9 |
| Debt / equity (x) | 0.00 | 0.02 |
| Cash from operations | 465 | 1,181 |
| Capex | (272) | (231) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · AKUMS DRUGS AND PHARMA L · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Profit before tax | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Net profit | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS (₹) | 4.37 | 4.26 | 9.64 | 4.15 | 2.66 | 4.33 | 5.53 | 6.53 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| CDMO | 3,485 | 80.0 |
| API | 184 | 4.2 |
| Domestic Branded Formulations | 210 | 4.8 |
| International Branded Formulations | 71 | 1.6 |
| Trade Generics | 50 | 1.2 |
| Domestic branded formulations | 237 | 5.4 |
| International branded formulations | 73 | 1.7 |
| Trade generics | 49 | 1.1 |
| Total, before eliminations | 4,359 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 37.5 | 30.1 | 98 of 158 | 38% |
| P/B | 3.3 | 3.0 | 93 of 163 | 43% |
| ROCE | 8.8 | 10.8 | 108 of 183 | 41% |
| ROE | 7.7 | 9.8 | 98 of 166 | 41% |
| Debt / Equity | 0.0 | 0.2 | 53 of 166 | 69% |
| EBITDA margin | 17.6 | 17.5 | 82 of 165 | 51% |
| Revenue growth | 13.9 | 16.3 | 84 of 161 | 48% |
| Profit growth | 56.1 | 30.9 | 60 of 158 | 62% |
| Market cap | 10950 | 810 | 41 of 181 | 78% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · AKUMS DRUGS AND PHARMA L · 28 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 15 Oct 2026 · Subsidiary gets Rs 52.75 cr NPPA demand notice over drug pricing | regulatory legal | high | — | — |
| 9 Oct 2026 · Routine RTA compliance certificate for Q2 FY27 dematerialisation | compliance | minimal | — | — |
| 25 Sept 2026 · Trading window closed from Oct 1 ahead of Q2 results | compliance | minimal | — | — |
| 23 Sept 2026 · Institutional Investor Meets on Sep 28-29, 2026 | board shareholder meetings | low | — | — |
| 16 Sept 2026 · Akums Drugs to participate in G200 Summit 2026 on Sept 22 | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Akums Drugs receives ESG rating of 65 from NSE Sustainability | business updates | medium | — | — |
| 25 Aug 2026 · Akums Drugs to attend Elara India Dialogue 2026 investor meet | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Akums Drugs cancels Aug 25 Investor Meet due to medical reasons | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Akums Drugs to attend Antique Healthcare Investor Conference on Aug 25 | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Q1 FY27 Earnings Call: Revenue Up 14%, EBITDA Up 35%, Confident on FY27 | investor communications | medium | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in